Published in Drug Week, January 28th, 2005
Firstly, the CHMP, at the request of the European Commission, re-examined its April 22, 2004, opinion on paroxetine in the light of additional information arising from newly available observational studies.
The CHMP, following the assessment of this additional information, confirmed its initial conclusion that the benefit/risk balance of paroxetine remains positive in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.